Madrid

• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• Effect of oxygen administration in the non-dependent lung on postoperative complications after lung surgery Recruiting
  2024-517599-39-00 6 2025-01-27 Lung Resection Surgery
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Phase I, open-label clinical trial to evaluate the safety and clinical response of repeated-dose intra-arterial infusion of autologous mesen … Recruiting
  2024-520427-86-00 1 2025-01-24 Autoimmune refractory epilepsy and Rasmussen Encephalitis
• A study to assess how Vaborem® is taking up in the body and tolerated in paediatric patients with serious infections. Recruiting
  2024-514656-32-00 4 2025-01-23 Suspected or confirmed Gram negative infections
• Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer Recruiting
  2024-516526-66-00 1 2025-01-21 Metastatic colorectal cancer and Gastric cancer
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizum … Recruiting
  2023-503675-24-00 5 2025-01-17 Triple-negative Breast Cancer
• COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE Recruiting
  2023-505868-11-00 5 2025-01-17 CHRONIC RENAL DISEASE
• A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca … Recruiting
  2024-511775-15-00 4 2025-01-17 Immune system diseases
• A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma Recruiting
  2024-514129-43-00 4 2025-01-15 Metastatic pancreatic ductal adenocarcinoma
• Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después … Recruiting
  2023-508741-40-00 10 2025-01-14 Non-small cell lung cancer
• An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting
  2024-512161-14-00 3 2025-01-14 Breast Cancer
• Efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity Recruiting
  2024-513004-33-00 4 2025-01-14 Hepatotoxicity
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During … Recruiting
  2024-511179-13-00 5 2025-01-13 Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
• A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad … Recruiting
  2023-509883-89-00 5 2025-01-09 Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
• A research study looking at long-term treatment with etavopivat in people with sickle cell disease or thalassaemia Recruiting
  2024-510805-27-00 5 2025-01-09 Sickle Cell Disease and Thalassaemia
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo … Recruiting
  2023-507560-39-00 5 2025-01-07 Acquired Antithrombin Deficiency (Heparin Resistance)
• Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon®) for Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery Recruiting
  2024-512798-29-00 5 2025-01-07 Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreat
• A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR … Recruiting
  2023-510109-16-00 4 2025-01-06 Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
• Oral antimicrobial treatment vs. outpatient parenteral for infective endocarditis Recruiting
  2024-519969-21-00 6 2025-01-01 Infective endocarditis
• Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies Recruiting
  2023-505204-34-00 1 2024-12-30 Mature B-Cell Neoplasm, Non-Hodgkin Lymphoma, Diffuse large B-cell lym
• Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread … Recruiting
  2024-511497-79-00 4 2024-12-30 Hormone receptor positive (HR+), human epidermal growth factor recepto

Showing 1,177–1,200 of 3,550 trials